Theravance Biopharma (TBPH) Competitors

$16.69 -0.33 (-1.93%)

As of 10:08 AM Eastern

TBPH vs. OGN, NAMS, ORKA, RCUS, and ALMS

Should you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Organon & Co. (OGN), NewAmsterdam Pharma (NAMS), Oruka Therapeutics (ORKA), Arcus Biosciences (RCUS), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry.

How does Theravance Biopharma compare to Organon & Co.?

Theravance Biopharma (NASDAQ:TBPH) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

: Theravance Biopharma has a net margin of 98.54% compared to Organon & Co.'s net margin of 3.99%. Organon & Co.'s return on equity of 99.95% beat Theravance Biopharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Theravance Biopharma 98.54% 16.76% 9.23%
Organon & Co. 3.99% 99.95% 6.22%
: Organon & Co. has higher revenue and earnings than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Theravance Biopharma $107.46M 8.00 $105.89M $2.03 8.22
Organon & Co. $6.22B 0.56 $187M $0.93 14.31
: 99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 6.9% of Theravance Biopharma shares are owned by insiders. Comparatively, 1.6% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Theravance Biopharma currently has a consensus target price of $21.83, suggesting a potential upside of 30.80%. Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 14.32%. Given Theravance Biopharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Theravance Biopharma is more favorable than Organon & Co..
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Theravance Biopharma
0 Sell rating(s)
4 Hold rating(s)

2 Buy rating(s)

2 Strong Buy rating(s)
2.75
Organon & Co.
3 Sell rating(s)

4 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.57
: In the previous week, Organon & Co. had 4 more articles in the media than Theravance Biopharma. MarketBeat recorded 9 mentions for Organon & Co. and 5 mentions for Theravance Biopharma. Organon & Co.'s average media sentiment score of 1.13 beat Theravance Biopharma's score of -0.38 indicating that Organon & Co. is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Theravance Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Organon & Co.
5 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
: Theravance Biopharma has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	98.54%	16.76%	9.23%
Organon & Co.	3.99%	99.95%	6.22%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	8.00	$105.89M	$2.03	8.22
Organon & Co.	$6.22B	0.56	$187M	$0.93	14.31

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.75
Organon & Co.	3 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.57

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organon & Co.	5 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Theravance Biopharma beats Organon & Co. on 10 of the 17 factors compared between the two stocks.

How does Theravance Biopharma compare to NewAmsterdam Pharma?

Theravance Biopharma (NASDAQ:TBPH) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

: Theravance Biopharma has a net margin of 98.54% compared to NewAmsterdam Pharma's net margin of -906.22%. Theravance Biopharma's return on equity of 16.76% beat NewAmsterdam Pharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Theravance Biopharma 98.54% 16.76% 9.23%
NewAmsterdam Pharma -906.22% -26.67% -24.82%
: Theravance Biopharma has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Theravance Biopharma $107.46M 8.00 $105.89M $2.03 8.22
NewAmsterdam Pharma $22.50M 201.96 -$203.82M -$1.73 N/A
: 99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 6.9% of Theravance Biopharma shares are owned by insiders. Comparatively, 20.8% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Theravance Biopharma currently has a consensus target price of $21.83, suggesting a potential upside of 30.80%. NewAmsterdam Pharma has a consensus target price of $48.00, suggesting a potential upside of 21.45%. Given Theravance Biopharma's higher probable upside, equities research analysts clearly believe Theravance Biopharma is more favorable than NewAmsterdam Pharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Theravance Biopharma
0 Sell rating(s)
4 Hold rating(s)

2 Buy rating(s)

2 Strong Buy rating(s)
2.75
NewAmsterdam Pharma
1 Sell rating(s)

1 Hold rating(s)

9 Buy rating(s)

1 Strong Buy rating(s)
2.83
: In the previous week, NewAmsterdam Pharma had 2 more articles in the media than Theravance Biopharma. MarketBeat recorded 7 mentions for NewAmsterdam Pharma and 5 mentions for Theravance Biopharma. NewAmsterdam Pharma's average media sentiment score of 0.76 beat Theravance Biopharma's score of -0.38 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Theravance Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
NewAmsterdam Pharma
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Theravance Biopharma has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	98.54%	16.76%	9.23%
NewAmsterdam Pharma	-906.22%	-26.67%	-24.82%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	8.00	$105.89M	$2.03	8.22
NewAmsterdam Pharma	$22.50M	201.96	-$203.82M	-$1.73	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.75
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Theravance Biopharma beats NewAmsterdam Pharma on 11 of the 17 factors compared between the two stocks.

How does Theravance Biopharma compare to Oruka Therapeutics?

Theravance Biopharma (NASDAQ:TBPH) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

: Theravance Biopharma has a net margin of 98.54% compared to Oruka Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of 16.76% beat Oruka Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Theravance Biopharma 98.54% 16.76% 9.23%
Oruka Therapeutics N/A -25.48% -24.34%
: Theravance Biopharma has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Theravance Biopharma $107.46M 8.00 $105.89M $2.03 8.22
Oruka Therapeutics N/A N/A -$105.43M -$1.86 N/A
: In the previous week, Theravance Biopharma and Theravance Biopharma both had 5 articles in the media. Oruka Therapeutics' average media sentiment score of 0.91 beat Theravance Biopharma's score of -0.38 indicating that Oruka Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Theravance Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Oruka Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 6.9% of Theravance Biopharma shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
: Theravance Biopharma has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.2, meaning that its share price is 120% less volatile than the S&P 500.
: Theravance Biopharma presently has a consensus target price of $21.83, suggesting a potential upside of 30.80%. Oruka Therapeutics has a consensus target price of $120.80, suggesting a potential upside of 85.92%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Oruka Therapeutics is more favorable than Theravance Biopharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Theravance Biopharma
0 Sell rating(s)
4 Hold rating(s)

2 Buy rating(s)

2 Strong Buy rating(s)
2.75
Oruka Therapeutics
1 Sell rating(s)

0 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.82

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	98.54%	16.76%	9.23%
Oruka Therapeutics	N/A	-25.48%	-24.34%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	8.00	$105.89M	$2.03	8.22
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.86	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oruka Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.75
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

Theravance Biopharma beats Oruka Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Theravance Biopharma compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

: Theravance Biopharma has a net margin of 98.54% compared to Arcus Biosciences' net margin of -156.36%. Theravance Biopharma's return on equity of 16.76% beat Arcus Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Arcus Biosciences -156.36% -68.97% -35.27%
Theravance Biopharma 98.54% 16.76% 9.23%
: In the previous week, Arcus Biosciences had 18 more articles in the media than Theravance Biopharma. MarketBeat recorded 23 mentions for Arcus Biosciences and 5 mentions for Theravance Biopharma. Arcus Biosciences' average media sentiment score of 0.14 beat Theravance Biopharma's score of -0.38 indicating that Arcus Biosciences is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcus Biosciences
3 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Theravance Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Arcus Biosciences presently has a consensus target price of $33.11, suggesting a potential upside of 33.24%. Theravance Biopharma has a consensus target price of $21.83, suggesting a potential upside of 30.80%. Given Arcus Biosciences' higher possible upside, equities research analysts plainly believe Arcus Biosciences is more favorable than Theravance Biopharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcus Biosciences
1 Sell rating(s)
3 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
2.64
Theravance Biopharma
0 Sell rating(s)

4 Hold rating(s)

2 Buy rating(s)

2 Strong Buy rating(s)
2.75
: Arcus Biosciences has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.
: 92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by company insiders. Comparatively, 6.9% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: Theravance Biopharma has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arcus Biosciences $247M 12.65 -$353M -$3.30 N/A
Theravance Biopharma $107.46M 8.00 $105.89M $2.03 8.22

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Theravance Biopharma	98.54%	16.76%	9.23%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Theravance Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Theravance Biopharma	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.75

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.65	-$353M	-$3.30	N/A
Theravance Biopharma	$107.46M	8.00	$105.89M	$2.03	8.22

Summary

Theravance Biopharma beats Arcus Biosciences on 9 of the 17 factors compared between the two stocks.

How does Theravance Biopharma compare to Alumis?

Alumis (NASDAQ:ALMS) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

: Theravance Biopharma has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alumis $24.05M 126.06 -$243.32M -$3.06 N/A
Theravance Biopharma $107.46M 8.00 $105.89M $2.03 8.22
: 99.1% of Theravance Biopharma shares are held by institutional investors. 40.7% of Alumis shares are held by company insiders. Comparatively, 6.9% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: Theravance Biopharma has a net margin of 98.54% compared to Alumis' net margin of -1,011.75%. Theravance Biopharma's return on equity of 16.76% beat Alumis' return on equity.
Company Net Margins Return on Equity Return on Assets
Alumis -1,011.75% -116.97% -88.43%
Theravance Biopharma 98.54% 16.76% 9.23%
: In the previous week, Theravance Biopharma had 4 more articles in the media than Alumis. MarketBeat recorded 5 mentions for Theravance Biopharma and 1 mentions for Alumis. Alumis' average media sentiment score of 0.00 beat Theravance Biopharma's score of -0.38 indicating that Alumis is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alumis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Theravance Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Alumis has a beta of -0.31, suggesting that its share price is 131% less volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.
: Alumis presently has a consensus target price of $38.60, suggesting a potential upside of 61.95%. Theravance Biopharma has a consensus target price of $21.83, suggesting a potential upside of 30.80%. Given Alumis' stronger consensus rating and higher possible upside, equities research analysts plainly believe Alumis is more favorable than Theravance Biopharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alumis
1 Sell rating(s)
0 Hold rating(s)

10 Buy rating(s)

1 Strong Buy rating(s)
2.92
Theravance Biopharma
0 Sell rating(s)

4 Hold rating(s)

2 Buy rating(s)

2 Strong Buy rating(s)
2.75

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	126.06	-$243.32M	-$3.06	N/A
Theravance Biopharma	$107.46M	8.00	$105.89M	$2.03	8.22

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-1,011.75%	-116.97%	-88.43%
Theravance Biopharma	98.54%	16.76%	9.23%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Theravance Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Theravance Biopharma	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.75

Summary

Theravance Biopharma beats Alumis on 11 of the 17 factors compared between the two stocks.

Get Theravance Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TBPH vs. The Competition

Export

Metric	Theravance Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$857.42M	$3.05B	$6.20B	$12.23B
Dividend Yield	N/A	1.88%	2.78%	5.25%
P/E Ratio	8.20	17.41	28.72	27.04
Price / Sales	8.00	291.10	529.04	75.91
Price / Cash	N/A	56.30	43.30	53.97
Price / Book	2.85	4.28	9.85	6.85
Net Income	$105.89M	$72.19M	$3.55B	$333.00M
7 Day Performance	N/A	N/A	N/A	0.15%
1 Month Performance	0.55%	4.18%	4.55%	6.79%
1 Year Performance	68.61%	46.15%	40.01%	39.95%

Theravance Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TBPH Theravance Biopharma	3.1684 of 5 stars	$16.69 -1.9%	$21.83 +30.8%	+70.4%	$857.42M	$107.46M	8.20	110	News Coverage Upcoming Earnings
OGN Organon & Co.	3.752 of 5 stars	$13.31 +0.3%	$11.40 -14.3%	+52.6%	$3.49B	$6.22B	14.31	10,000	Insider Trade
NAMS NewAmsterdam Pharma	3.8881 of 5 stars	$29.89 +0.1%	$48.00 +60.6%	+86.0%	$3.44B	$22.50M	N/A	4	News Coverage Earnings Report
ORKA Oruka Therapeutics	3.2754 of 5 stars	$66.10 -0.5%	$120.80 +82.8%	+573.7%	$3.32B	N/A	N/A	N/A	Upcoming Earnings
RCUS Arcus Biosciences	2.4566 of 5 stars	$26.45 +1.5%	$32.44 +22.7%	+212.6%	$3.31B	$247M	N/A	500	Trending News Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TBPH) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Theravance Biopharma (TBPH) Competitors

TBPH vs. OGN, NAMS, ORKA, RCUS, and ALMS

How does Theravance Biopharma compare to Organon & Co.?

Summary

How does Theravance Biopharma compare to NewAmsterdam Pharma?

Summary

How does Theravance Biopharma compare to Oruka Therapeutics?

Summary

How does Theravance Biopharma compare to Arcus Biosciences?

Summary

How does Theravance Biopharma compare to Alumis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH vs. The Competition

Theravance Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Theravance Biopharma (TBPH) Competitors

TBPH vs. OGN, NAMS, ORKA, RCUS, and ALMS

How does Theravance Biopharma compare to Organon & Co.?

Summary

How does Theravance Biopharma compare to NewAmsterdam Pharma?

Summary

How does Theravance Biopharma compare to Oruka Therapeutics?

Summary

How does Theravance Biopharma compare to Arcus Biosciences?

Summary

How does Theravance Biopharma compare to Alumis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH vs. The Competition

Theravance Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools